Relmada Therapeutics (RLMD) Financials: Revenue & Earnings

RLMD price $3.23 +0.01 +0.47%

Ticker
RLMD
Price
$3.23
Change
+0.01 +0.47%
Market cap ?
$344.01M
P/E ?
-3.55
Dividend yield ?
0.00%
Beta ?
0.45
Sector
Healthcare
Industry
Biotechnology

Financials

2016201720182019202020212022202320242025
0000000000

Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready…

Fair value

RLMD fair value Not meaningful. Price $3.23.

Fair value is an estimate of what one share is worth if future cash flows arrive as modeled. It is not a forecast of the share price. How discounted cash flow works.

Not meaningful

Compare RLMD

Earnings

DateEPS actualEPS estimateRevenueRevenue estimate
2026-11-12—-0.14——
2026-08-06-0.11-0.20——
2026-05-12-0.22-0.18——
2026-03-19-0.27-0.14——
2025-11-13-0.30-0.04——
2025-08-07-0.30-0.25——
2025-05-12-0.58-0.31——
2025-03-27-0.62-0.70——
2024-11-07-0.72-0.65——
2024-08-07-0.59-0.83——
2024-05-08-0.72-0.90——
2024-03-19-0.84-0.88——
2023-11-08-0.73-0.95——
2023-08-08-0.84-0.92——
2023-05-11-0.87-0.88——
2023-03-23-1.26-1.33——
2022-11-10-1.31-1.40——
2022-08-11-1.33-1.30——
2022-05-05-1.40-1.21——
2022-03-23-1.80-1.60——
2021-11-11-2.44-1.62——
2021-08-10-1.56-1.47——
2021-05-12-1.34-1.39——
2021-03-23-1.28-1.11——
2020-11-12-1.05-0.86——
2020-08-12-0.73-0.55——
2020-05-15-0.72-0.33——
2020-03-26-0.39-0.36——
2019-11-13-0.38———
2019-09-24-0.44———
2019-05-14-0.36———
2019-02-13-1.12———
2018-11-13-1.08———
2018-09-28-1.07———
2018-05-14-1.04———
2018-02-12-0.44———
2017-11-14-0.32———
2017-09-28-0.52———
2017-05-15-0.66———
2017-02-10-0.34———

Dividends

Yield 0.00%. Payout ratio 0.00%. Frequency —.

Safety score 37/100 · Watch. Payout ratio is 0% of earnings. Free-cash-flow coverage is not available, so this part stays neutral. No dividend history was found. There is no dividend yield.

Ex-dateDividendRecordPaymentFrequency
No data yet.

Insider trades

DateInsiderActionSharesPriceValue
2026-09-10Shenouda MagedBuy79.80K$4.25339.15K
2026-09-10TRAVERSA SERGIOBuy100.00K$4.10410.00K
2026-09-09Shenouda MagedBuy120.20K$4.20504.84K
2026-09-09TRAVERSA SERGIOBuy100.00K$4.18418.00K
2025-12-15TRAVERSA SERGIOBuy27.50K$4.12113.30K
2025-12-15Shenouda MagedBuy11.66K$4.1248.06K
2025-12-12TRAVERSA SERGIOBuy1.20M$4.064.86M
2025-12-12Shenouda MagedBuy828.00K$4.063.36M
2025-12-12Ence ChuckBuy828.00K$4.063.36M
2025-12-12Fedeli FabianaBuy164.00K$4.06665.84K
2025-12-12GLASSPOOL JOHNBuy164.00K$4.06665.84K
2025-12-12Kelly Paul EdwardBuy828.00K$4.063.36M
2025-12-12CASAMENTO CHARLES JBuy164.00K$4.06665.84K
2025-11-05Shenouda MagedBuy500.00K$2.201.10M
2025-11-05Ence ChuckBuy136.00K$2.20299.20K
2025-11-05TRAVERSA SERGIOBuy272.50K$2.20599.50K
2025-11-05Kelly Paul EdwardBuy90.00K$2.20198.00K
2025-08-28TRAVERSA SERGIOBuy55.98K$0.7441.42K
2025-08-27TRAVERSA SERGIOBuy129.46K$0.6786.73K
2025-08-26TRAVERSA SERGIOBuy80.55K$0.6249.94K
2025-06-26Ence ChuckBuy400.00K$0.67268.00K
2025-06-26Shenouda MagedBuy600.00K$0.67402.00K
2025-06-26TRAVERSA SERGIOBuy800.00K$0.67536.00K
2025-06-26CASAMENTO CHARLES JBuy100.00K$0.6767.00K
2025-06-26GLASSPOOL JOHNBuy100.00K$0.6767.00K
2025-06-26Fedeli FabianaBuy100.00K$0.6767.00K
2025-06-26Kelly Paul EdwardBuy400.00K$0.67268.00K
2025-05-20Shenouda MagedBuy60.00K$0.5231.42K
2025-05-20TRAVERSA SERGIOBuy147.69K$0.5682.25K
2025-05-19Shenouda MagedBuy90.00K$0.4943.69K
2025-05-19TRAVERSA SERGIOBuy30.00K$0.5014.99K
2025-05-16Kelly Paul EdwardBuy200.00K$0.4386.06K
2025-05-16Shenouda MagedBuy50.00K$0.4422.10K
2025-05-16Ence ChuckBuy228.96K$0.45103.33K
2025-05-16TRAVERSA SERGIOBuy172.31K$0.4577.47K
2024-10-22CASAMENTO CHARLES JSell13.00K——
2024-09-11TRAVERSA SERGIOBuy51.41K$2.99153.71K
2024-09-11Shenouda MagedBuy24.12K$2.9571.15K
2024-09-10TRAVERSA SERGIOBuy33.01K$2.7590.79K
2024-09-10Shenouda MagedBuy21.12K$2.7357.65K
2024-09-09TRAVERSA SERGIOBuy55.58K$2.71150.62K
2024-09-09CASAMENTO CHARLES JBuy13.00K$2.5633.28K
2024-09-09Shenouda MagedBuy8.19K$2.5520.89K
2024-09-09Kelly Paul EdwardBuy25.00K$2.5964.75K
2024-05-24TRAVERSA SERGIOBuy122.36K$2.48303.45K
2024-05-24TRAVERSA SERGIOSell122.36K$2.48303.45K
2024-05-24Shenouda MagedBuy54.62K$2.48135.47K
2024-05-24Shenouda MagedSell54.62K$2.48135.47K
2024-05-24Kelly Paul EdwardBuy43.70K$2.48108.38K
2024-05-24Kelly Paul EdwardSell43.70K$2.48108.38K
2024-05-24GLASSPOOL JOHNBuy20.98K$2.4852.02K
2024-05-24GLASSPOOL JOHNSell20.98K$2.4852.02K
2024-05-24Fedeli FabianaBuy20.98K$2.4852.02K
2024-05-24Fedeli FabianaSell20.98K$2.4852.02K
2024-05-24Ence ChuckBuy54.62K$2.48135.47K
2024-05-24Ence ChuckSell54.62K$2.48135.47K
2024-05-24CASAMENTO CHARLES JBuy20.98K$2.4852.02K
2024-05-24CASAMENTO CHARLES JSell20.98K$2.4852.02K
2024-01-31TRAVERSA SERGIOBuy27.46K$4.00109.75K
2024-01-31Shenouda MagedBuy6.88K$4.0627.94K
2024-01-31Ence ChuckBuy13.67K$4.0555.43K
2024-01-30TRAVERSA SERGIOBuy41.00K$3.90159.95K
2024-01-30Shenouda MagedBuy15.00K$3.8958.32K
2024-01-30Ence ChuckBuy14.50K$3.8756.05K
2024-01-29TRAVERSA SERGIOBuy31.54K$3.71117.04K
2024-01-29Shenouda MagedBuy10.80K$3.6539.45K
2024-01-29Ence ChuckBuy10.80K$3.6539.44K
2023-12-15TRAVERSA SERGIOBuy183.88K$2.48456.02K
2023-12-15Shenouda MagedBuy82.09K$2.48203.58K
2023-12-15Kelly Paul EdwardBuy65.67K$2.48162.87K
2023-12-15GLASSPOOL JOHNBuy31.52K$2.4878.17K
2023-12-15Fedeli FabianaBuy31.52K$2.4878.17K
2023-12-15Ence ChuckBuy82.09K$2.48203.58K
2023-12-15CASAMENTO CHARLES JBuy31.52K$2.4878.17K
2023-05-25TRAVERSA SERGIOBuy527.21K$3.371.78M
2023-05-25Shenouda MagedBuy317.64K$3.371.07M
2023-05-25SCHMIDT ERIC THOMASBuy92.96K$3.37313.27K
2023-05-25Kelly Paul EdwardBuy92.96K$3.37313.27K
2023-05-25GLASSPOOL JOHNBuy92.96K$3.37313.27K
2023-05-25Fedeli FabianaBuy200.00K$4.22844.00K
2023-05-25Ence ChuckBuy321.24K$3.371.08M
2023-05-25CASAMENTO CHARLES JBuy92.96K$3.37313.27K
2023-05-23O'Gorman CedricBuy10.00K$3.1831.80K
2023-01-12Fedeli FabianaOther0——
2023-01-12Fedeli FabianaOther———
2023-01-06O'Gorman CedricSell400.00K——
2023-01-06O'Gorman CedricSell0——
2022-12-31CASAMENTO CHARLES JOther0——
2022-12-16TRAVERSA SERGIOSell300.00K——
2022-12-16Shenouda MagedSell200.00K——
2022-12-16Ence ChuckSell200.00K——
2022-12-16TRAVERSA SERGIOBuy323.52K——
2022-12-16Shenouda MagedBuy194.92K——
2022-12-16SCHMIDT ERIC THOMASBuy57.04K——
2022-12-16Kelly Paul EdwardBuy57.04K——
2022-12-16GLASSPOOL JOHNBuy57.04K——
2022-12-16Ence ChuckBuy197.12K——
2022-12-16CASAMENTO CHARLES JBuy57.04K——
2022-12-08TRAVERSA SERGIOBuy55.25K$2.10115.80K
2022-09-28TRAVERSA SERGIOSell87.50K$33.432.93M

Institutional holders

Latest filed quarter: Q2 2026.

Institutions holding: 131, holders +23 vs prior quarter. Ownership 90.09%.

HolderSharesChangeChange %Value
JUPITER TOPCO LLC11.16M11.16MNew77.32M
BLACKROCK, INC.7.43M6.14M+475.92%51.39M
SQUADRON CAPITAL MANAGEMENT LLC7.35M-1.12M-13.27%50.86M
VENROCK ADVISER, LLC6.84M2.00M+41.31%47.36M
SPRUCE STREET CAPITAL LP6.39M129.21K+2.06%44.23M
ADAGE CAPITAL PARTNERS GP, L.L.C.4.76M00.00%32.96M
VANGUARD CAPITAL MANAGEMENT LLC4.46M1.38M+44.97%30.86M
JONES HILL CAPITAL LP3.66M3.31M+966.39%25.29M
ORBIMED ADVISORS LLC3.63M-1.08M-23.00%25.13M
STATE STREET CORP2.52M2.16M+605.12%17.42M
GEODE CAPITAL MANAGEMENT, LLC2.49M1.64M+193.70%17.25M
MILLENNIUM MANAGEMENT LLC2.36M-1.55M-39.55%16.34M
MARSHALL WACE, LLP2.25M-2.23M-49.87%15.55M
IKARIAN CAPITAL, LLC2.15M-540.00K-20.09%14.87M
DRIEHAUS CAPITAL MANAGEMENT LLC2.13M00.00%14.75M
AMERIPRISE FINANCIAL INC1.94M347.03K+21.81%13.41M
EVENTIDE ASSET MANAGEMENT, LLC1.86M1.02M+120.69%12.86M
BALYASNY ASSET MANAGEMENT L.P.1.52M1.27M+502.36%10.52M
STEMPOINT CAPITAL LP1.46M862.68K+144.40%10.10M
COMMODORE CAPITAL LP1.43M791.10K+124.80%9.86M
POLAR CAPITAL HOLDINGS PLC1.34M-74.19K-5.24%9.28M
CITADEL ADVISORS LLC1.06M1.04M+4268.99%7.35M
SIO CAPITAL MANAGEMENT, LLC1.00M38.56K+4.00%6.94M
OPALEYE MANAGEMENT INC.935.00K00.00%6.47M
VANGUARD PORTFOLIO MANAGEMENT LLC898.20K898.20KNew6.22M

Earnings and financials

Relmada Therapeutics, Inc. (RLMD) trades at $3.23, with a market cap of $344.01M and a trailing P/E of -3.55. Revenue below is the annual history on file. It describes what the business has already reported. It is not a forecast and it is not a recommendation.

Financials

2016201720182019202020212022202320242025
0000000000

Insights · Dividends · Forecast · Financials · Learn

Stocklytics home · Screener

Relmada Therapeutics (RLMD) Financials: Revenue & Earnings

RLMD$3.23+0.01 +0.47%

$344.01M

Market Cap

-3.55

P/E

—

Forward P/E

—

Score

Price History